Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population?

被引:11
作者
Fabrizi, Fabrizio [1 ]
Messa, Piergiorgio [1 ]
机构
[1] IRCCS Fdn, Div Nephrol, Maggiore Hosp, Milan, Italy
关键词
dialysis; direct-acting anti-virals; hepatitis C; interferon; ribavirin; SUSTAINED VIROLOGICAL RESPONSE; ANTIVIRAL TRIPLE THERAPY; TREATMENT-NAIVE PATIENTS; SEVERE RENAL IMPAIRMENT; LOW-DOSE RIBAVIRIN; PEGINTERFERON ALPHA-2A; RECEIVING HEMODIALYSIS; VIRUS-INFECTION; PHARMACOKINETICS; BOCEPREVIR;
D O I
10.1586/17512433.2015.1086266
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The advent of direct-acting anti-viral (DAA) drugs is dramatically changing the treatment of hepatitis C virus (HCV) in patients with intact kidney function (cure rates' >90% and infrequent adverse events). The information on efficacy and safety of DAAs for HCV therapy in patients with renal failure is limited. We have reviewed the available evidence regarding efficacy and safety of numerous DAAs (boceprevir, telaprevir, sofosbuvir, simeprevir, grazoprevir, elbasvir, ombitasvir, paritaprevir, ritonavir, dasabuvir, ledispavir, daclatasvir, asunaprevir, beclabuvir) in treating HCV-infected patients with renal impairment and/or end-stage renal disease. The major limitation of this review is the paucity of published data and its reliance on abstracts and product monographs. Preliminary data suggest that combination antiviral therapy (grazoprevir and elbasvir) is provided with great efficacy in patients with HCV genotype 1 and chronic kidney disease stage 4 or 5 including those on intermittent dialysis, SVR12, 99% (114/115), according to a per-protocol analysis. In another trial, patients with HCV genotype 1 and chronic kidney disease stage 4 or 5 were given the 3D regimen; an interim evaluation reported that all patients completing treatment to date had viral response (100%, 14/14) but data on sustained viral response are under evaluation. Treatments were generally well tolerated.
引用
收藏
页码:785 / 793
页数:9
相关论文
共 46 条
[1]  
AASLD IDSA HCV Guidance Panel, 2015, HEPATOLOGY
[2]   THE EFFECT OF RENAL IMPAIRMENT ON MULTIPLE-DOSE PHARMACOKINETICS OF THE FIXED-DOSE COMBINATION OF DACLATASVIR/ASUNAPREVIR/BECLABUVIR [J].
Adamczyk, R. ;
Sims, K. ;
Hesney, M. ;
Wind-Rotolo, M. ;
Stonier, M. ;
Penn, R. ;
Reynolds, L. ;
LaCreta, F. ;
AbuTarif, M. .
JOURNAL OF HEPATOLOGY, 2015, 62 :S628-S628
[3]  
[Anonymous], INFECT DIS LOND
[4]  
[Anonymous], J GASTROENTEROL HEPA
[5]   Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection [J].
Bacon, Bruce R. ;
Gordon, Stuart C. ;
Lawitz, Eric ;
Marcellin, Patrick ;
Vierling, John M. ;
Zeuzem, Stefan ;
Poordad, Fred ;
Goodman, Zachary D. ;
Sings, Heather L. ;
Poordad, Fred ;
Goodman, Zachary D. ;
Sings, Heather L. ;
Boparai, Navdeep ;
Burroughs, Margaret ;
Brass, Clifford A. ;
Albrecht, Janice K. ;
Esteban, Rafael .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (13) :1207-1217
[6]  
Bhamidimarri K, 2014, 65 ANN M AASLD NOV 7
[7]   FIRST RIBAVIRIN-FREE SOFOSBUVIR AND SIMEPREVIR TREATMENT OF HEPATITIS C GENOTYPE 1 PATIENTS WITH SEVERE RENAL IMPAIRMENT (GFR <30 mL/min OR DIALYSIS) [J].
Czul, F. ;
Schiff, E. ;
Peyton, A. ;
Levy, C. ;
Hernandez, M. ;
Jeffers, L. ;
O'Brien, C. ;
Martin, P. ;
Bhamidimarri, K. R. .
JOURNAL OF HEPATOLOGY, 2015, 62 :S670-S671
[8]   Telaprevir pharmacokinetics in a hepatitis C virus infected patient on haemodialysis [J].
de Kanter, Clara T. M. M. ;
den Hollander, Jan G. ;
Verweij-van Wissen, Corrien P. W. G. M. ;
Burger, David M. .
JOURNAL OF CLINICAL VIROLOGY, 2014, 60 (04) :431-432
[9]   Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: Is it feasible? [J].
Dumortier, Jerome ;
Guillaud, Olivier ;
Gagnieu, Marie-Claude ;
Janbon, Benedicte ;
Juillard, Laurent ;
Morelon, Emmanuel ;
Leroy, Vincent .
JOURNAL OF CLINICAL VIROLOGY, 2013, 56 (02) :146-149
[10]   Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies [J].
Fabrizi, F. ;
Dixit, V. ;
Messa, P. ;
Martin, P. .
JOURNAL OF VIRAL HEPATITIS, 2014, 21 (10) :681-689